Your browser doesn't support javascript.
loading
Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.
Weisberg, Ellen; Meng, Chengcheng; Case, Abigail E; Sattler, Martin; Tiv, Hong L; Gokhale, Prafulla C; Buhrlage, Sara J; Liu, Xiaoxi; Yang, Jing; Wang, Jinhua; Gray, Nathanael; Stone, Richard M; Adamia, Sophia; Dubreuil, Patrice; Letard, Sebastien; Griffin, James D.
Afiliação
  • Weisberg E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Meng C; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Case AE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Tiv HL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Gokhale PC; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Buhrlage SJ; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Liu X; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Yang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Wang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Gray N; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Stone RM; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Adamia S; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Dubreuil P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Letard S; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Br J Haematol ; 187(4): 488-501, 2019 11.
Article em En | MEDLINE | ID: mdl-31309543
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Inibidores de Proteínas Quinases / Proteínas Mutantes / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Inibidores de Proteínas Quinases / Proteínas Mutantes / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article